Health Utility Elicitation Lisa A. ProsserScott D. GrosseEve Wittenberg Editorial 11 October 2012 Pages: 83 - 86
Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payer’s Perspective Aurea DuranNishan SenguptaMichael Lees Original Research Article 11 October 2012 Pages: 87 - 101
Granulocyte-Colony Stimulating Factor Use and Medical Costs after Initial Adjuvant Chemotherapy in Older Patients with Early-Stage Breast Cancer Robert I. GriffithsRichard L. BarronGary H. Lyman Original Research Article 11 October 2012 Pages: 103 - 118
Incorporating Calibrated Model Parameters into Sensitivity Analyses Douglas TaylorVivek PawarMilton C. Weinstein Short Communication 11 October 2012 Pages: 119 - 126
Real Economics Needs to Reflect Real Decisions Mark SculpherKarl Claxton Commentary 11 October 2012 Pages: 133 - 136
Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Hip or Knee Surgery Michael HolmesChristopher CarrollDiana Papaioannou Review Article 11 October 2012 Pages: 137 - 146
Osteoporotic Fractures Sangeeta BudhiaYeshi MikyasEnkhe Badamgarav Review Article 11 October 2012 Pages: 147 - 170